Abstract
Rituximab is a CD 20 monoclonal antibody drug used in various spectrum of diseases today. It has proven to be a boon, especially in the field of dermatology. Although Rituximab was initially introduced as a novel method to treat B-cell Non Hodgkin Lymphoma, its use has rapidly expanded to include a number of other Lymphomas and Autoimmune diseases.This review is to give a bird’s eye view of updates on rituximab.
 Conclusion: With its horizons expanding in dermatology, and with better information regarding its efficacy and safety profile, Rituximab has now become an approved first‑line therapy for pemphigus. In conclusion, Rituximab has proven to be a substantial boon for dermatologists in difficult to treat cases.
Highlights
Rituximab is a CD 20 monoclonal antibody drug used in various spectrum of diseases today
Levine [29] has expressed that both muscle symptoms and cutaneous signs improve following Rituximab administration according to the lymphoma protocol
The success of Rituximab has led to the creation of dozens of monoclonal antibodies that have birthed a new field of medical therapeutics
Summary
The journey to the discovery and approval of Rituximab has been long and slow. The seed of the idea to use monoclonal antibodies to treat Rituximab was a monoclonal antibody drug cancer occurred to Dr César Milstein and Dr brought to market in 1996 and revolutionized the. Georges Köhler, two NCI (National Cancer Institute) funded researchers who perceived that the cancer cells could be attacked by isolating proteins specific to these cells. They came up with the idea of producing antibodies which would selectively eliminate target cells with those proteins.They called these “monoclonal antibodies” [1]. In 1986, Muromonab , the first monoclonal antibody was released which targeted CD03 proteins [2] It had a clinical use in treatment acute graft rejection of kidney transplant. Efforts to create a monoclonal antibody to target this protein to treat B cell lymphomas began. It has been used in various conditions which involve the pemphigus group of disorders and a number of other cutaneous disorders which we have discussed below
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
